drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00078 | DB10429 | 1,172 | 200 | [
"DDInter898",
"DDInter282"
] | Ibritumomab tiuxetan | Candida albicans | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1172,
24,
200
]
],
[
[
1172,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1172,
25,
976
],
[
976,
24,
200
]
],
[
[
1172,
24,
738
],
[
738,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"U... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Tofaciti... |
DB00673 | DB09083 | 723 | 880 | [
"DDInter112",
"DDInter996"
] | Aprepitant | Ivabradine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
723,
25,
880
]
],
[
[
723,
25,
1478
],
[
1478,
24,
880
]
],
[
[
723,
24,
159
],
[
159,
63,
880
]
],
[
[
723,
24,
1040
],
[
1040,
... | [
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may... | Aprepitant may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may ca... |
DB00191 | DB06204 | 73 | 768 | [
"DDInter1447",
"DDInter1746"
] | Phentermine | Tapentadol | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Major | 2 | [
[
[
73,
25,
768
]
],
[
[
73,
6,
6112
],
[
6112,
45,
768
]
],
[
[
73,
21,
28921
],
[
28921,
60,
768
]
],
[
[
73,
24,
1383
],
[
1383,
... | [
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
],
[
[
"Phentermine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tapen... | Phentermine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Tapentadol (Compound)
Phentermine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Tapentadol (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate a... |
DB01148 | DB01246 | 1,128 | 820 | [
"DDInter738",
"DDInter45"
] | Flavoxate | Alimemazine | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1128,
24,
820
]
],
[
[
1128,
63,
104
],
[
104,
40,
820
]
],
[
[
1128,
63,
401
],
[
401,
24,
820
]
],
[
[
1128,
24,
649
],
[
649,
... | [
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB00323 | DB06282 | 1,062 | 516 | [
"DDInter1829",
"DDInter1053"
] | Tolcapone | Levocetirizine | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1062,
24,
516
]
],
[
[
1062,
63,
701
],
[
701,
24,
516
]
],
[
[
1062,
24,
1614
],
[
1614,
24,
516
]
],
[
[
1062,
24,
407
],
[
407,
... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilo... |
DB05239 | DB06414 | 866 | 655 | [
"DDInter425",
"DDInter703"
] | Cobimetinib | Etravirine | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Major | 2 | [
[
[
866,
25,
655
]
],
[
[
866,
63,
1101
],
[
1101,
23,
655
]
],
[
[
866,
64,
1057
],
[
1057,
24,
655
]
],
[
[
866,
63,
1051
],
[
1051,
... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etravirine"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Cobimetinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause ... |
DB00812 | DB11095 | 998 | 235 | [
"DDInter1451",
"DDInter505"
] | Phenylbutazone | Desirudin | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
998,
25,
235
]
],
[
[
998,
24,
1151
],
[
1151,
24,
235
]
],
[
[
998,
24,
738
],
[
738,
63,
235
]
],
[
[
998,
63,
121
],
[
121,
2... | [
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Suni... | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Ni... |
DB01095 | DB11989 | 671 | 1,434 | [
"DDInter769",
"DDInter183"
] | Fluvastatin | Benznidazole | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
671,
24,
1434
]
],
[
[
671,
1,
788
],
[
788,
24,
1434
]
],
[
[
671,
24,
375
],
[
375,
24,
1434
]
],
[
[
671,
24,
148
],
[
148,
6... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Fluvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a... | Fluvastatin (Compound) resembles Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderat... |
DB08931 | DB09098 | 947 | 98 | [
"DDInter1600",
"DDInter1700"
] | Riociguat | Somatrem | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
947,
24,
98
]
],
[
[
947,
63,
609
],
[
609,
24,
98
]
],
[
[
947,
24,
124
],
[
124,
63,
98
]
],
[
[
947,
24,
1450
],
[
1450,
24,
... | [
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
... | Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Gla... |
DB00773 | DB01229 | 896 | 973 | [
"DDInter702",
"DDInter1377"
] | Etoposide | Paclitaxel | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
896,
24,
973
]
],
[
[
896,
24,
310
],
[
310,
63,
973
]
],
[
[
896,
5,
11582
],
[
11582,
44,
973
]
],
[
[
896,
6,
7524
],
[
7524,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Etoposide (Compound) treats lung cancer (Disease) and lung cancer (Disease) is treated by Paclitaxel (Compound)... |
DB00916 | DB12834 | 112 | 148 | [
"DDInter1202",
"DDInter1649"
] | Metronidazole | Secnidazole | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
112,
24,
148
]
],
[
[
112,
24,
1593
],
[
1593,
24,
148
]
],
[
[
112,
63,
597
],
[
597,
24,
148
]
],
[
[
112,
1,
458
],
[
458,
24... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
... | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenico... |
DB00086 | DB01381 | 1,167 | 958 | [
"DDInter1712",
"DDInter819"
] | Streptokinase | Ginkgo biloba | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Moderate | 1 | [
[
[
1167,
24,
958
]
],
[
[
1167,
24,
1347
],
[
1347,
24,
958
]
],
[
[
1167,
25,
126
],
[
126,
24,
958
]
],
[
[
1167,
25,
792
],
[
792,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Streptokinase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may... |
DB09080 | DB12825 | 144 | 1,375 | [
"DDInter1331",
"DDInter1032"
] | Olodaterol | Lefamulin | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
144,
24,
1375
]
],
[
[
144,
24,
659
],
[
659,
24,
1375
]
],
[
[
144,
63,
455
],
[
455,
24,
1375
]
],
[
[
144,
64,
290
],
[
290,
... | [
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
... | Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmete... |
DB00397 | DB00657 | 1,466 | 1,360 | [
"DDInter1458",
"DDInter1130"
] | Phenylpropanolamine | Mecamylamine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. | Moderate | 1 | [
[
[
1466,
24,
1360
]
],
[
[
1466,
21,
28722
],
[
28722,
60,
1360
]
],
[
[
1466,
24,
1344
],
[
1344,
63,
1360
]
],
[
[
1466,
35,
22
],
[
22... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecamylamine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side E... | Phenylpropanolamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Mecamylamine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases whe... |
DB00552 | DB01073 | 1,238 | 1,488 | [
"DDInter1425",
"DDInter745"
] | Pentostatin | Fludarabine | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Major | 2 | [
[
[
1238,
25,
1488
]
],
[
[
1238,
40,
11221
],
[
11221,
1,
1488
]
],
[
[
1238,
5,
11555
],
[
11555,
44,
1488
]
],
[
[
1238,
21,
29106
],
[
... | [
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
]
],
[
[
"Pentostatin",
"{u} (Compound) resembles {v} (Compound)",
"Vidarabine"
],
[
"Vidarabine",
"{u} (Compound) resembles {v} (Compo... | Pentostatin (Compound) resembles Vidarabine (Compound) and Vidarabine (Compound) resembles Fludarabine (Compound)
Pentostatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound)
Pentostatin (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect)... |
DB01229 | DB12035 | 973 | 943 | [
"DDInter1377",
"DDInter1641"
] | Paclitaxel | Sarecycline | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
973,
24,
943
]
],
[
[
973,
24,
1670
],
[
1670,
24,
943
]
],
[
[
973,
63,
147
],
[
147,
24,
943
]
],
[
[
973,
24,
1619
],
[
1619,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinb... |
DB00851 | DB00978 | 611 | 739 | [
"DDInter463",
"DDInter1084"
] | Dacarbazine | Lomefloxacin | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Minor | 0 | [
[
[
611,
23,
739
]
],
[
[
611,
23,
945
],
[
945,
40,
739
]
],
[
[
611,
62,
1176
],
[
1176,
1,
739
]
],
[
[
611,
62,
1467
],
[
1467,
... | [
[
[
"Dacarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Dacarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
... | Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (... |
DB00434 | DB06282 | 13 | 516 | [
"DDInter459",
"DDInter1053"
] | Cyproheptadine | Levocetirizine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
13,
24,
516
]
],
[
[
13,
23,
771
],
[
771,
62,
516
]
],
[
[
13,
24,
1074
],
[
1074,
63,
516
]
],
[
[
13,
63,
701
],
[
701,
24,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
... | Cyproheptadine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Iodide ... |
DB09564 | DB14276 | 1,296 | 1,631 | [
"DDInter930",
"DDInter1892"
] | Insulin degludec | Turmeric | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Moderate | 1 | [
[
[
1296,
24,
1631
]
],
[
[
1296,
63,
1479
],
[
1479,
23,
1631
]
],
[
[
1296,
63,
1281
],
[
1281,
24,
1631
]
],
[
[
1296,
24,
433
],
[
433... | [
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Turmeric"
]
],
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic a... | Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Turmeric
Insulin degludec may cause a moderate interaction that could exacerbate diseases when take... |
DB00488 | DB15091 | 196 | 676 | [
"DDInter57",
"DDInter1901"
] | Altretamine | Upadacitinib | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
196,
25,
676
]
],
[
[
196,
63,
1461
],
[
1461,
23,
676
]
],
[
[
196,
24,
1430
],
[
1430,
24,
676
]
],
[
[
196,
63,
597
],
[
597,
... | [
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin... | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipu... |
DB00400 | DB01224 | 353 | 623 | [
"DDInter843",
"DDInter1553"
] | Griseofulvin | Quetiapine | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
353,
24,
623
]
],
[
[
353,
6,
8374
],
[
8374,
45,
623
]
],
[
[
353,
21,
28681
],
[
28681,
60,
623
]
],
[
[
353,
24,
1297
],
[
1297,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Quetiapine (Compound)
Griseofulvin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Quetiapine (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01324 | DB09043 | 178 | 135 | [
"DDInter1490",
"DDInter36"
] | Polythiazide | Albiglutide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
178,
24,
135
]
],
[
[
178,
62,
126
],
[
126,
23,
135
]
],
[
[
178,
63,
1647
],
[
1647,
23,
135
]
],
[
[
178,
1,
323
],
[
323,
24... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Polythiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
... | Polythiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose ma... |
DB08822 | DB11827 | 911 | 433 | [
"DDInter156",
"DDInter669"
] | Azilsartan medoxomil | Ertugliflozin | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
911,
24,
433
]
],
[
[
911,
63,
251
],
[
251,
24,
433
]
],
[
[
911,
40,
217
],
[
217,
24,
433
]
],
[
[
911,
24,
1455
],
[
1455,
2... | [
[
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Beta... | Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Azilsartan medoxomil (Compound) resembles Olmesartan (Compound) and Olmesartan may cause a mo... |
DB00008 | DB01076 | 491 | 700 | [
"DDInter1407",
"DDInter133"
] | Peginterferon alfa-2a | Atorvastatin | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
491,
24,
700
]
],
[
[
491,
24,
788
],
[
788,
1,
700
]
],
[
[
491,
24,
126
],
[
126,
23,
700
]
],
[
[
491,
24,
896
],
[
896,
24,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pit... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor i... |
DB00063 | DB03404 | 366 | 765 | [
"DDInter659",
"DDInter855"
] | Eptifibatide | Hemin | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Moderate | 1 | [
[
[
366,
24,
765
]
],
[
[
366,
25,
840
],
[
840,
63,
765
]
],
[
[
366,
25,
291
],
[
291,
24,
765
]
],
[
[
366,
24,
1061
],
[
1061,
2... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
... | Eptifibatide may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Eptifibatide may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interac... |
DB14004 | DB14444 | 398 | 151 | [
"DDInter1806",
"DDInter924"
] | Tildrakizumab | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis. The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasi... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
398,
24,
151
]
],
[
[
398,
63,
66
],
[
66,
24,
151
]
],
[
[
398,
64,
375
],
[
375,
24,
151
]
],
[
[
398,
25,
676
],
[
676,
63,
... | [
[
[
"Tildrakizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Tildrakizumab",
"{u} may cause a moderate interaction that c... | Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tildrakizumab may lead to a major ... |
DB08816 | DB09280 | 578 | 1,604 | [
"DDInter1802",
"DDInter1101"
] | Ticagrelor | Lumacaftor | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
578,
25,
1604
]
],
[
[
578,
63,
1171
],
[
1171,
24,
1604
]
],
[
[
578,
25,
292
],
[
292,
24,
1604
]
],
[
[
578,
24,
1427
],
[
1427,
... | [
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
[
"Meloxicam",... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Ticagrelor may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause ... |
DB11581 | DB14783 | 1,456 | 287 | [
"DDInter1926",
"DDInter574"
] | Venetoclax | Diroximel fumarate | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1456,
24,
287
]
],
[
[
1456,
63,
1101
],
[
1101,
24,
287
]
],
[
[
1456,
64,
384
],
[
384,
24,
287
]
],
[
[
1456,
24,
1583
],
[
1583,
... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Venetoclax may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib ma... |
DB01069 | DB09481 | 401 | 460 | [
"DDInter1533",
"DDInter1113"
] | Promethazine | Magnesium carbonate | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
401,
23,
460
]
],
[
[
401,
63,
664
],
[
664,
23,
460
]
],
[
[
401,
24,
1592
],
[
1592,
23,
460
]
],
[
[
401,
74,
216
],
[
216,
2... | [
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Nebivolo... |
DB01591 | DB12010 | 667 | 214 | [
"DDInter1696",
"DDInter785"
] | Solifenacin | Fostamatinib | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
667,
24,
214
]
],
[
[
667,
63,
723
],
[
723,
24,
214
]
],
[
[
667,
24,
1250
],
[
1250,
24,
214
]
],
[
[
667,
64,
1166
],
[
1166,
... | [
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Paz... |
DB00344 | DB00682 | 1,302 | 126 | [
"DDInter1543",
"DDInter1951"
] | Protriptyline | Warfarin | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
1302,
24,
126
]
],
[
[
1302,
40,
847
],
[
847,
40,
126
]
],
[
[
1302,
24,
1376
],
[
1376,
40,
126
]
],
[
[
1302,
25,
1053
],
[
1053,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) re... | Protriptyline (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Warfarin (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Warfarin (Compound)
Protriptyline may lead to a major ... |
DB00586 | DB05773 | 1,512 | 1,047 | [
"DDInter537",
"DDInter1848"
] | Diclofenac | Trastuzumab emtansine | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
1512,
24,
1047
]
],
[
[
1512,
24,
848
],
[
848,
24,
1047
]
],
[
[
1512,
64,
886
],
[
886,
24,
1047
]
],
[
[
1512,
24,
643
],
[
643,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Diclofenac may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may... |
DB01259 | DB06663 | 392 | 1,154 | [
"DDInter1024",
"DDInter1398"
] | Lapatinib | Pasireotide | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
392,
25,
1154
]
],
[
[
392,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
392,
62,
112
],
[
112,
23,
1154
]
],
[
[
392,
23,
907
],
[
907,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Lapatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by ... | Lapatinib (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken w... |
DB06779 | DB06822 | 365 | 802 | [
"DDInter470",
"DDInter1812"
] | Dalteparin | Tinzaparin | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Major | 2 | [
[
[
365,
25,
802
]
],
[
[
365,
23,
944
],
[
944,
62,
802
]
],
[
[
365,
63,
222
],
[
222,
24,
802
]
],
[
[
365,
24,
1427
],
[
1427,
6... | [
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Dalteparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Dalteparin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine... |
DB00652 | DB00792 | 234 | 832 | [
"DDInter1421",
"DDInter1878"
] | Pentazocine | Tripelennamine | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
234,
24,
832
]
],
[
[
234,
24,
100
],
[
100,
63,
832
]
],
[
[
234,
24,
649
],
[
649,
1,
832
]
],
[
[
234,
63,
1594
],
[
1594,
24... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Clofe... |
DB01267 | DB06691 | 519 | 849 | [
"DDInter1381",
"DDInter1155"
] | Paliperidone | Mepyramine | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
519,
24,
849
]
],
[
[
519,
63,
1594
],
[
1594,
24,
849
]
],
[
[
519,
6,
12523
],
[
12523,
45,
849
]
],
[
[
519,
24,
407
],
[
407,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Paliperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Paliperidone m... |
DB00193 | DB01246 | 534 | 820 | [
"DDInter1841",
"DDInter45"
] | Tramadol | Alimemazine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | A phenothiazine derivative that is used as an antipruritic. | Major | 2 | [
[
[
534,
25,
820
]
],
[
[
534,
25,
104
],
[
104,
40,
820
]
],
[
[
534,
25,
401
],
[
401,
24,
820
]
],
[
[
534,
24,
649
],
[
649,
1,
... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} ... | Tramadol may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Tramadol may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when... |
DB00978 | DB05812 | 739 | 1,374 | [
"DDInter1084",
"DDInter8"
] | Lomefloxacin | Abiraterone | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
739,
24,
1374
]
],
[
[
739,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
739,
62,
112
],
[
112,
23,
1374
]
],
[
[
739,
63,
1494
],
[
1494,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Acute coronary syndrome"
],
[
"Acute coronary syndrome",... | Lomefloxacin (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clini... |
DB00619 | DB08870 | 1,419 | 850 | [
"DDInter909",
"DDInter228"
] | Imatinib | Brentuximab vedotin | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1419,
24,
850
]
],
[
[
1419,
24,
671
],
[
671,
24,
850
]
],
[
[
1419,
24,
496
],
[
496,
63,
850
]
],
[
[
1419,
25,
1671
],
[
1671,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Va... |
DB00691 | DB01234 | 1,058 | 1,220 | [
"DDInter1237",
"DDInter513"
] | Moexipril | Dexamethasone | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1058,
24,
1220
]
],
[
[
1058,
63,
870
],
[
870,
1,
1220
]
],
[
[
1058,
63,
175
],
[
175,
40,
1220
]
],
[
[
1058,
24,
167
],
[
167,
... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexam... |
DB00872 | DB11967 | 1,080 | 710 | [
"DDInter438",
"DDInter210"
] | Conivaptan | Binimetinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1080,
24,
710
]
],
[
[
1080,
25,
1593
],
[
1593,
24,
710
]
],
[
[
1080,
64,
1557
],
[
1557,
24,
710
]
],
[
[
1080,
63,
883
],
[
883,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotini... | Conivaptan may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Conivaptan may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate int... |
DB00227 | DB00307 | 1,463 | 1,101 | [
"DDInter1098",
"DDInter202"
] | Lovastatin | Bexarotene | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Moderate | 1 | [
[
[
1463,
24,
1101
]
],
[
[
1463,
6,
8374
],
[
8374,
45,
1101
]
],
[
[
1463,
21,
28762
],
[
28762,
60,
1101
]
],
[
[
1463,
25,
609
],
[
60... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Lovastatin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bexarotene (Compound)
Lovastatin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bexarotene (Compound)
Lovastatin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin ma... |
DB09237 | DB11986 | 1,586 | 484 | [
"DDInter1045",
"DDInter648"
] | Levamlodipine | Entrectinib | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1586,
24,
484
]
],
[
[
1586,
23,
466
],
[
466,
62,
484
]
],
[
[
1586,
64,
467
],
[
467,
24,
484
]
],
[
[
1586,
63,
1478
],
[
1478,
... | [
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Levamlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
... | Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Levamlodipine may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin m... |
DB05812 | DB12010 | 1,374 | 214 | [
"DDInter8",
"DDInter785"
] | Abiraterone | Fostamatinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1374,
24,
214
]
],
[
[
1374,
64,
690
],
[
690,
24,
214
]
],
[
[
1374,
24,
861
],
[
861,
63,
214
]
],
[
[
1374,
63,
866
],
[
866,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifabutin"
],
[
"Rifabut... | Abiraterone may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may caus... |
DB01075 | DB09420 | 1,376 | 1,074 | [
"DDInter569",
"DDInter953"
] | Diphenhydramine | Iodide I-123 | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
1376,
24,
1074
]
],
[
[
1376,
24,
516
],
[
516,
24,
1074
]
],
[
[
1376,
63,
902
],
[
902,
24,
1074
]
],
[
[
1376,
40,
126
],
[
126,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with C... |
DB00213 | DB11901 | 837 | 913 | [
"DDInter1388",
"DDInter107"
] | Pantoprazole | Apalutamide | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
837,
24,
913
]
],
[
[
837,
24,
279
],
[
279,
24,
913
]
],
[
[
837,
63,
600
],
[
600,
24,
913
]
],
[
[
837,
25,
1250
],
[
1250,
2... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole an... |
DB00843 | DB08865 | 479 | 1,593 | [
"DDInter583",
"DDInter448"
] | Donepezil | Crizotinib | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Minor | 0 | [
[
[
479,
23,
1593
]
],
[
[
479,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
479,
7,
2900
],
[
2900,
46,
1593
]
],
[
[
479,
18,
2023
],
[
2023,
... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Donepezil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Donepezil (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Crizotinib (Compound)
Donepezil (Compound) downregulates RAP1GAP (Gene) and RAP1GAP (Gene) is upregulated by Crizotinib (Compound)
Donepezil (Co... |
DB00230 | DB11186 | 784 | 1,609 | [
"DDInter1516",
"DDInter1427"
] | Pregabalin | Pentoxyverine | Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evide... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
784,
24,
1609
]
],
[
[
784,
24,
104
],
[
104,
24,
1609
]
],
[
[
784,
25,
475
],
[
475,
24,
1609
]
],
[
[
784,
24,
104
],
[
104,
... | [
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Pregabalin may lead to a major life threatening interaction when taken with Morphine and Morphine may cau... |
DB00023 | DB15091 | 305 | 676 | [
"DDInter127",
"DDInter1901"
] | Asparaginase Escherichia coli | Upadacitinib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
305,
25,
676
]
],
[
[
305,
24,
1430
],
[
1430,
24,
676
]
],
[
[
305,
24,
1184
],
[
1184,
25,
676
]
],
[
[
305,
25,
1064
],
[
1064,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Si... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate di... |
DB00366 | DB00776 | 1,594 | 1,335 | [
"DDInter600",
"DDInter1360"
] | Doxylamine | Oxcarbazepine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
1594,
24,
1335
]
],
[
[
1594,
24,
1264
],
[
1264,
63,
1335
]
],
[
[
1594,
40,
11233
],
[
11233,
1,
1335
]
],
[
[
1594,
24,
1236
],
[
1... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Doxylamine (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Oxcarbazepine (Compound... |
DB00031 | DB04865 | 20 | 4 | [
"DDInter1764",
"DDInter1335"
] | Tenecteplase | Omacetaxine mepesuccinate | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
20,
25,
4
]
],
[
[
20,
24,
738
],
[
738,
63,
4
]
],
[
[
20,
25,
39
],
[
39,
63,
4
]
],
[
[
20,
25,
1213
],
[
1213,
24,
4
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Tenecteplase may lead to a major life threatening interaction when taken with Panobinostat and Pa... |
DB01177 | DB14568 | 77 | 982 | [
"DDInter904",
"DDInter1000"
] | Idarubicin | Ivosidenib | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
77,
25,
982
]
],
[
[
77,
62,
112
],
[
112,
23,
982
]
],
[
[
77,
25,
976
],
[
976,
24,
982
]
],
[
[
77,
63,
700
],
[
700,
24,
... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Idarubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Idarubicin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may ca... |
DB01611 | DB11901 | 1,487 | 913 | [
"DDInter893",
"DDInter107"
] | Hydroxychloroquine | Apalutamide | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1487,
24,
913
]
],
[
[
1487,
63,
112
],
[
112,
23,
913
]
],
[
[
1487,
24,
110
],
[
110,
62,
913
]
],
[
[
1487,
62,
1247
],
[
1247,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidaz... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00366 | DB01215 | 1,594 | 1,418 | [
"DDInter600",
"DDInter677"
] | Doxylamine | Estazolam | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Moderate | 1 | [
[
[
1594,
24,
1418
]
],
[
[
1594,
24,
523
],
[
523,
1,
1418
]
],
[
[
1594,
24,
1216
],
[
1216,
40,
1418
]
],
[
[
1594,
63,
905
],
[
905,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Estazolam (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Estazolam (Compound)
Do... |
DB01225 | DB11793 | 500 | 738 | [
"DDInter645",
"DDInter1297"
] | Enoxaparin | Niraparib | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
500,
24,
738
]
],
[
[
500,
25,
1213
],
[
1213,
24,
738
]
],
[
[
500,
64,
1578
],
[
1578,
24,
738
]
],
[
[
500,
63,
443
],
[
443,
... | [
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Enoxaparin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Enoxaparin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interacti... |
DB00201 | DB00563 | 1,684 | 663 | [
"DDInter263",
"DDInter1174"
] | Caffeine | Methotrexate | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but ... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
1684,
24,
663
]
],
[
[
1684,
6,
4973
],
[
4973,
45,
663
]
],
[
[
1684,
18,
15501
],
[
15501,
57,
663
]
],
[
[
1684,
21,
28681
],
[
286... | [
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Caffeine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Methotrexate (Compound)
Caffeine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Methotrexate (Compound)
Caffeine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate... |
DB01088 | DB11793 | 714 | 738 | [
"DDInter908",
"DDInter1297"
] | Iloprost | Niraparib | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
714,
24,
738
]
],
[
[
714,
25,
1213
],
[
1213,
24,
738
]
],
[
[
714,
63,
1578
],
[
1578,
24,
738
]
],
[
[
714,
64,
202
],
[
202,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Iloprost may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderat... |
DB01267 | DB04843 | 519 | 1,511 | [
"DDInter1381",
"DDInter1149"
] | Paliperidone | Mepenzolate | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
519,
24,
1511
]
],
[
[
519,
63,
537
],
[
537,
24,
1511
]
],
[
[
519,
24,
649
],
[
649,
1,
1511
]
],
[
[
519,
21,
28975
],
[
28975,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
... | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clo... |
DB00471 | DB14723 | 201 | 159 | [
"DDInter1242",
"DDInter1026"
] | Montelukast | Larotrectinib | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
201,
24,
159
]
],
[
[
201,
24,
1375
],
[
1375,
24,
159
]
],
[
[
201,
63,
529
],
[
529,
24,
159
]
],
[
[
201,
24,
1654
],
[
1654,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
... | Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fl... |
DB00595 | DB00653 | 1,545 | 544 | [
"DDInter1374",
"DDInter1120"
] | Oxytetracycline | Magnesium sulfate | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Moderate | 1 | [
[
[
1545,
24,
544
]
],
[
[
1545,
24,
1473
],
[
1473,
63,
544
]
],
[
[
1545,
40,
1669
],
[
1669,
63,
544
]
],
[
[
1545,
40,
1572
],
[
1572,... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium ... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Oxytetracycline (Compound) resembles Minocycline (Compound) and Minocycline may ca... |
DB00978 | DB11827 | 739 | 433 | [
"DDInter1084",
"DDInter669"
] | Lomefloxacin | Ertugliflozin | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
739,
24,
433
]
],
[
[
739,
25,
959
],
[
959,
24,
433
]
],
[
[
739,
63,
521
],
[
521,
24,
433
]
],
[
[
739,
64,
251
],
[
251,
24,... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glip... | Lomefloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cau... |
DB08870 | DB13873 | 850 | 1,534 | [
"DDInter228",
"DDInter719"
] | Brentuximab vedotin | Fenofibric acid | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Moderate | 1 | [
[
[
850,
24,
1534
]
],
[
[
850,
63,
267
],
[
267,
24,
1534
]
],
[
[
850,
24,
1613
],
[
1613,
24,
1534
]
],
[
[
850,
64,
1377
],
[
1377,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalt... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB08815 | DB11730 | 154 | 351 | [
"DDInter1104",
"DDInter1588"
] | Lurasidone | Ribociclib | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
154,
25,
351
]
],
[
[
154,
24,
466
],
[
466,
62,
351
]
],
[
[
154,
63,
222
],
[
222,
23,
351
]
],
[
[
154,
25,
283
],
[
283,
62,... | [
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sib... |
DB00264 | DB01041 | 88 | 770 | [
"DDInter1200",
"DDInter1789"
] | Metoprolol | Thalidomide | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
88,
24,
770
]
],
[
[
88,
6,
10215
],
[
10215,
45,
770
]
],
[
[
88,
21,
28789
],
[
28789,
60,
770
]
],
[
[
88,
24,
849
],
[
849,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Metoprolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound... | Metoprolol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Metoprolol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Metoprolol may cause a moderate interaction that could exacerbate diseases when ta... |
DB08901 | DB09122 | 1,468 | 1,613 | [
"DDInter1492",
"DDInter1409"
] | Ponatinib | Peginterferon beta-1a | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1468,
24,
1613
]
],
[
[
1468,
63,
671
],
[
671,
24,
1613
]
],
[
[
1468,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1468,
25,
1155
],
[
1155... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidio... |
DB00218 | DB00637 | 1,176 | 1,557 | [
"DDInter1247",
"DDInter128"
] | Moxifloxacin | Astemizole | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Major | 2 | [
[
[
1176,
25,
1557
]
],
[
[
1176,
23,
112
],
[
112,
62,
1557
]
],
[
[
1176,
24,
770
],
[
770,
63,
1557
]
],
[
[
1176,
25,
79
],
[
79,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Astemizole
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and... |
DB00005 | DB00277 | 1,057 | 1,031 | [
"DDInter687",
"DDInter1791"
] | Etanercept | Theophylline | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
1057,
24,
1031
]
],
[
[
1057,
24,
523
],
[
523,
62,
1031
]
],
[
[
1057,
25,
1096
],
[
1096,
62,
1031
]
],
[
[
1057,
24,
1072
],
[
1072... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline
Etanercept may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic a... |
DB00776 | DB01259 | 1,335 | 392 | [
"DDInter1360",
"DDInter1024"
] | Oxcarbazepine | Lapatinib | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1335,
24,
392
]
],
[
[
1335,
6,
8374
],
[
8374,
45,
392
]
],
[
[
1335,
18,
3385
],
[
3385,
57,
392
]
],
[
[
1335,
21,
29429
],
[
29429... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Oxcarbazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Oxcarbazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Oxcarbazepine (Compound) downregulates SDC1 (Gene) and SDC1 (Gene) is downregulated by Lapatinib (Compound)
Oxcarbazepine (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatin... |
DB00619 | DB01253 | 1,419 | 628 | [
"DDInter909",
"DDInter664"
] | Imatinib | Ergometrine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Moderate | 1 | [
[
[
1419,
24,
628
]
],
[
[
1419,
63,
1131
],
[
1131,
40,
628
]
],
[
[
1419,
24,
469
],
[
469,
40,
628
]
],
[
[
1419,
6,
8374
],
[
8374,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergometrine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methysergide"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Methysergide (Compound) resembles Ergometrine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine (Compound) resembles Ergometrine (Co... |
DB01115 | DB12130 | 336 | 1,017 | [
"DDInter1291",
"DDInter1094"
] | Nifedipine | Lorlatinib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
336,
24,
1017
]
],
[
[
336,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
336,
63,
175
],
[
175,
24,
1017
]
],
[
[
336,
40,
409
],
[
409,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triam... |
DB06699 | DB11915 | 774 | 1,293 | [
"DDInter493",
"DDInter1909"
] | Degarelix | Valbenazine | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
774,
24,
1293
]
],
[
[
774,
62,
112
],
[
112,
23,
1293
]
],
[
[
774,
40,
521
],
[
521,
24,
1293
]
],
[
[
774,
63,
401
],
[
401,
... | [
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Degarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Degarelix (Compound) resembles Goserelin (Compound) and Goserelin may cause a moderate interaction that could ... |
DB00331 | DB00603 | 1,645 | 303 | [
"DDInter1164",
"DDInter1137"
] | Metformin | Medroxyprogesterone acetate | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Moderate | 1 | [
[
[
1645,
24,
303
]
],
[
[
1645,
24,
167
],
[
167,
1,
303
]
],
[
[
1645,
18,
6718
],
[
6718,
57,
303
]
],
[
[
1645,
21,
28956
],
[
28956,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortiso... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Metformin (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Medroxyprogesterone acetate (Compound)
Metformin (C... |
DB01023 | DB12010 | 409 | 214 | [
"DDInter716",
"DDInter785"
] | Felodipine | Fostamatinib | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
409,
24,
214
]
],
[
[
409,
40,
1428
],
[
1428,
24,
214
]
],
[
[
409,
63,
723
],
[
723,
24,
214
]
],
[
[
409,
24,
866
],
[
866,
2... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Felodipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moder... | Felodipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that cou... |
DB00631 | DB01004 | 372 | 563 | [
"DDInter405",
"DDInter806"
] | Clofarabine | Ganciclovir | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
372,
24,
563
]
],
[
[
372,
63,
1295
],
[
1295,
1,
563
]
],
[
[
372,
24,
387
],
[
387,
1,
563
]
],
[
[
372,
24,
248
],
[
248,
40,... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
],
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir and Valaciclovir (Compound) resembles Ganciclovir (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Acyclovir and Acyclovir (Compound) resembles Ganciclovir (Comp... |
DB09039 | DB12332 | 1,670 | 1,619 | [
"DDInter629",
"DDInter1626"
] | Eliglustat | Rucaparib | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1670,
24,
1619
]
],
[
[
1670,
63,
307
],
[
307,
23,
1619
]
],
[
[
1670,
64,
271
],
[
271,
23,
1619
]
],
[
[
1670,
23,
1135
],
[
1135,
... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Eliglustat may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a min... |
DB00978 | DB01177 | 739 | 77 | [
"DDInter1084",
"DDInter904"
] | Lomefloxacin | Idarubicin | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Minor | 0 | [
[
[
739,
23,
77
]
],
[
[
739,
21,
28987
],
[
28987,
60,
77
]
],
[
[
739,
1,
1467
],
[
1467,
23,
77
]
],
[
[
739,
40,
1299
],
[
1299,
... | [
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Chills"
],
[
"Chills",
"{u} (Side Effect) is caused b... | Lomefloxacin (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Idarubicin (Compound)
Lomefloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Lomefloxacin (Compound) resembles Trovafloxacin (Com... |
DB00580 | DB11730 | 311 | 351 | [
"DDInter1910",
"DDInter1588"
] | Valdecoxib | Ribociclib | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
311,
24,
351
]
],
[
[
311,
24,
112
],
[
112,
23,
351
]
],
[
[
311,
24,
283
],
[
283,
62,
351
]
],
[
[
311,
24,
372
],
[
372,
24,... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fe... |
DB00559 | DB12015 | 152 | 1,033 | [
"DDInter223",
"DDInter53"
] | Bosentan | Alpelisib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
152,
24,
1033
]
],
[
[
152,
24,
1135
],
[
1135,
23,
1033
]
],
[
[
152,
24,
1344
],
[
1344,
24,
1033
]
],
[
[
152,
63,
10
],
[
10,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"N... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozi... |
DB06414 | DB11691 | 655 | 1,499 | [
"DDInter703",
"DDInter1258"
] | Etravirine | Naldemedine | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
655,
24,
1499
]
],
[
[
655,
63,
723
],
[
723,
24,
1499
]
],
[
[
655,
24,
1670
],
[
1670,
24,
1499
]
],
[
[
655,
25,
1406
],
[
1406,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eligl... |
DB00440 | DB08898 | 1,548 | 524 | [
"DDInter1874",
"DDInter828"
] | Trimethoprim | Glucarpidase | Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in comb... | Glucarpidase is a recombinant carboxypeptidase G2 produced by genetically modified _Escherichia coli_ bacteria. It is a 390-amino acid homodimer protein. High-dose [methotrexate], an antifolate agent, has been widely and safely used for many decades in treating various cancers; however, even with aggressive hydration, ... | Moderate | 1 | [
[
[
1548,
24,
524
]
],
[
[
1548,
40,
304
],
[
304,
24,
524
]
],
[
[
1548,
63,
929
],
[
929,
24,
524
]
],
[
[
1548,
25,
1147
],
[
1147,
... | [
[
[
"Trimethoprim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glucarpidase"
]
],
[
[
"Trimethoprim",
"{u} (Compound) resembles {v} (Compound)",
"Trimetrexate"
],
[
"Trimetrexate",
"{u} may cause... | Trimethoprim (Compound) resembles Trimetrexate (Compound) and Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Glucarpidase
Trimethoprim may cause a moderate interaction that could exacerbate diseases when taken with Pyrimethamine and Pyrimethamine may cause a moderate intera... |
DB00812 | DB01222 | 998 | 617 | [
"DDInter1451",
"DDInter246"
] | Phenylbutazone | Budesonide | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
998,
24,
617
]
],
[
[
998,
63,
251
],
[
251,
1,
617
]
],
[
[
998,
24,
1220
],
[
1220,
1,
617
]
],
[
[
998,
6,
8374
],
[
8374,
45... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
... | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Bu... |
DB11979 | DB12301 | 1,320 | 907 | [
"DDInter625",
"DDInter585"
] | Elagolix | Doravirine | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Moderate | 1 | [
[
[
1320,
24,
907
]
],
[
[
1320,
63,
1478
],
[
1478,
23,
907
]
],
[
[
1320,
24,
159
],
[
159,
62,
907
]
],
[
[
1320,
64,
760
],
[
760,
... | [
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
]
],
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"... | Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectin... |
DB00757 | DB11915 | 1,166 | 1,293 | [
"DDInter581",
"DDInter1909"
] | Dolasetron | Valbenazine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Major | 2 | [
[
[
1166,
25,
1293
]
],
[
[
1166,
23,
112
],
[
112,
23,
1293
]
],
[
[
1166,
64,
521
],
[
521,
24,
1293
]
],
[
[
1166,
25,
401
],
[
401,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Dolasetron may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause... |
DB00047 | DB00263 | 176 | 1,029 | [
"DDInter932",
"DDInter1727"
] | Insulin glargine | Sulfisoxazole | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. | Moderate | 1 | [
[
[
176,
24,
1029
]
],
[
[
176,
24,
1247
],
[
1247,
40,
1029
]
],
[
[
176,
24,
161
],
[
161,
1,
1029
]
],
[
[
176,
24,
245
],
[
245,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxa... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) r... |
DB00029 | DB00063 | 25 | 366 | [
"DDInter99",
"DDInter659"
] | Anistreplase | Eptifibatide | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Major | 2 | [
[
[
25,
25,
366
]
],
[
[
25,
23,
944
],
[
944,
62,
366
]
],
[
[
25,
24,
914
],
[
914,
63,
366
]
],
[
[
25,
24,
1595
],
[
1595,
24,
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
]
],
[
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomi... | Anistreplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Eptifibatide
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflun... |
DB00816 | DB00850 | 1,674 | 1,630 | [
"DDInter1346",
"DDInter1432"
] | Orciprenaline | Perphenazine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
1674,
24,
1630
]
],
[
[
1674,
63,
252
],
[
252,
40,
1630
]
],
[
[
1674,
24,
673
],
[
673,
40,
1630
]
],
[
[
1674,
64,
684
],
[
684,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Perphena... |
DB00446 | DB11691 | 597 | 1,499 | [
"DDInter351",
"DDInter1258"
] | Chloramphenicol | Naldemedine | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
597,
24,
1499
]
],
[
[
597,
23,
307
],
[
307,
23,
1499
]
],
[
[
597,
24,
932
],
[
932,
24,
1499
]
],
[
[
597,
24,
960
],
[
960,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
... | Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone and... |
DB05273 | DB09074 | 507 | 1,362 | [
"DDInter1638",
"DDInter1327"
] | Samarium (153Sm) lexidronam | Olaparib | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
507,
25,
1362
]
],
[
[
507,
25,
725
],
[
725,
63,
1362
]
],
[
[
507,
64,
896
],
[
896,
24,
1362
]
],
[
[
507,
25,
250
],
[
250,
... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
... | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Etoposide and E... |
DB01246 | DB01261 | 820 | 170 | [
"DDInter45",
"DDInter1679"
] | Alimemazine | Sitagliptin | A phenothiazine derivative that is used as an antipruritic. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
820,
24,
170
]
],
[
[
820,
6,
8374
],
[
8374,
45,
170
]
],
[
[
820,
21,
28787
],
[
28787,
60,
170
]
],
[
[
820,
24,
52
],
[
52,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Alimemazine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Sitagliptin (Compound)
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide ... |
DB00607 | DB12267 | 1,249 | 1,476 | [
"DDInter1256",
"DDInter233"
] | Nafcillin | Brigatinib | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
1249,
25,
1476
]
],
[
[
1249,
24,
1135
],
[
1135,
23,
1476
]
],
[
[
1249,
62,
168
],
[
168,
23,
1476
]
],
[
[
1249,
24,
629
],
[
629,
... | [
[
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may... |
DB01229 | DB01406 | 973 | 984 | [
"DDInter1378",
"DDInter472"
] | Paclitaxel (protein-bound) | Danazol | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
973,
24,
984
]
],
[
[
973,
6,
10450
],
[
10450,
45,
984
]
],
[
[
973,
18,
8224
],
[
8224,
46,
984
]
],
[
[
973,
7,
3833
],
[
3833,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP19A1"
],
[
"CYP19A1",
"{u} (Gene) is bound by {v} (Compound)",
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Paclitaxel (Compound) binds CYP19A1 (Gene) and CYP19A1 (Gene) is bound by Danazol (Compound)
Paclitaxel (Compound) downregulates P4HA2 (Gene) and P4HA2 (Gene) is upregulated by Danazol (Compound)
Paclitaxel (Compound) upr... |
DB00790 | DB01156 | 664 | 593 | [
"DDInter1431",
"DDInter252"
] | Perindopril | Bupropion | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
664,
24,
593
]
],
[
[
664,
21,
29220
],
[
29220,
60,
593
]
],
[
[
664,
63,
322
],
[
322,
24,
593
]
],
[
[
664,
40,
1638
],
[
1638,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Perindopril",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain upper"
],
[
"Abdominal pain upper",
"{u... | Perindopril (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Bupropion (Compound)
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases ... |
DB00188 | DB01045 | 168 | 463 | [
"DDInter222",
"DDInter1590"
] | Bortezomib | Rifampicin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Major | 2 | [
[
[
168,
25,
463
]
],
[
[
168,
25,
690
],
[
690,
40,
463
]
],
[
[
168,
6,
7950
],
[
7950,
45,
463
]
],
[
[
168,
7,
8155
],
[
8155,
4... | [
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} (Co... | Bortezomib may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Rifampicin (Compound)
Bortezomib (Compound) upregulates ABCC5 (Gene) and ABCC5 (Gene) is bound by Rifampi... |
DB00963 | DB01240 | 1,263 | 885 | [
"DDInter241",
"DDInter657"
] | Bromfenac | Epoprostenol | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1263,
24,
885
]
],
[
[
1263,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1263,
21,
28719
],
[
28719,
60,
885
]
],
[
[
1263,
63,
1512
],
[
1512... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Bromfenac (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Epoprostenol (Compound)
Bromfenac may cause a moderate interaction that ... |
DB00153 | DB06410 | 1,331 | 1,196 | [
"DDInter662",
"DDInter595"
] | Ergocalciferol | Doxercalciferol | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Major | 2 | [
[
[
1331,
25,
1196
]
],
[
[
1331,
23,
1142
],
[
1142,
23,
1196
]
],
[
[
1331,
24,
359
],
[
359,
24,
1196
]
],
[
[
1331,
24,
853
],
[
853,
... | [
[
[
"Ergocalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Ergocalciferol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orlistat"
],
[
"O... | Ergocalciferol may cause a minor interaction that can limit clinical effects when taken with Orlistat and Orlistat may cause a minor interaction that can limit clinical effects when taken with Doxercalciferol
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide a... |
DB00387 | DB00792 | 1,386 | 832 | [
"DDInter1528",
"DDInter1878"
] | Procyclidine | Tripelennamine | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1386,
24,
832
]
],
[
[
1386,
24,
100
],
[
100,
63,
832
]
],
[
[
1386,
24,
649
],
[
649,
1,
832
]
],
[
[
1386,
63,
1594
],
[
1594,
... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Clo... |
DB00580 | DB08820 | 311 | 1,478 | [
"DDInter1910",
"DDInter997"
] | Valdecoxib | Ivacaftor | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
311,
24,
1478
]
],
[
[
311,
24,
1411
],
[
1411,
24,
1478
]
],
[
[
311,
63,
245
],
[
245,
24,
1478
]
],
[
[
311,
24,
1040
],
[
1040,
... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glim... |
DB08899 | DB09083 | 129 | 880 | [
"DDInter649",
"DDInter996"
] | Enzalutamide | Ivabradine | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
129,
25,
880
]
],
[
[
129,
63,
480
],
[
480,
24,
880
]
],
[
[
129,
64,
1478
],
[
1478,
24,
880
]
],
[
[
129,
25,
159
],
[
159,
6... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formot... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Enzalutamide may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may caus... |
DB00531 | DB12332 | 450 | 1,619 | [
"DDInter456",
"DDInter1626"
] | Cyclophosphamide | Rucaparib | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
450,
24,
1619
]
],
[
[
450,
23,
307
],
[
307,
23,
1619
]
],
[
[
450,
24,
112
],
[
112,
23,
1619
]
],
[
[
450,
24,
259
],
[
259,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
... | Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole an... |
DB00991 | DB13620 | 97 | 948 | [
"DDInter1358",
"DDInter1499"
] | Oxaprozin | Potassium gluconate | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Moderate | 1 | [
[
[
97,
24,
948
]
],
[
[
97,
24,
848
],
[
848,
24,
948
]
],
[
[
97,
63,
1512
],
[
1512,
24,
948
]
],
[
[
97,
40,
998
],
[
998,
24,
... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and D... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.